This is a routine Form 144 for an officer selling shares to cover tax obligations from vesting restricted stock. The amount is negligible relative to market cap. No material impact expected; continue to monitor for any cluster of insider selling activity.
Price Chart
Executive Summary
Officer Michael R. Megna filed a Form 144 to sell 4,600 Class A ordinary shares of Kiniksa Pharmaceuticals, with an approximate market value of $369,380. The shares were acquired via restricted stock lapse on September 1, 2026, and the proposed sale appears to be a routine equity compensation exercise. Given the negligible size (less than 0.01% of the $6.2B market cap), this filing carries no material signaling impact.
Key Facts
- Insider: Michael R. Megna, Officer of Kiniksa Pharmaceuticals International, plc
- Proposed sale of 4,600 Class A ordinary shares
- Approximate market value: $369,380
- Shares acquired on 09/01/2026 via Restricted Stock Lapse (equity compensation)
- Broker: Charles Schwab & Co., Inc.
- Filing date: 09/03/2026
- Company market cap: $6.2B
Financial Impact
Proposed sale of 4,600 Class A ordinary shares valued at approximately $369,380, representing less than 0.01% of the company's $6.2B market capitalization.
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (KNSA) — Batch item 1 | 0001921094-26-000988 |
| Document: 0001921094-26-000988-index.html | 0001921094-26-000988 |
| Document: 0001921094-26-000988.txt | 0001921094-26-000988 |
| 144 Filing (KNSA) — Batch item 4 | 0001921094-26-000988 |
| Document: 0001921094-26-000988-index.html | 0001921094-26-000988 |
| Document: 0001921094-26-000988.txt | 0001921094-26-000988 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $76.00 | awaiting T+60 | — | $72.98 (−3.97%) |
Oct 27, 2026 today | Press Release | $75.00 | awaiting T+60 | — | $72.98 (−2.69%) |
Oct 22, 2026 5d ago | 8-K | $76.73 | awaiting T+60 | — | $72.98 (−4.89%) |
Oct 22, 2026 5d ago | Press Release | $80.79 | awaiting T+60 | — | $72.98 (−9.67%) |
Sep 3, 2026 7w ago | 144 | $77.91 | awaiting T+60 | — | $72.98 (−6.33%) |
Jul 28, 2026 13w ago | 8-K | $79.44 $79.70 | ▲ +0.33% | ▼ −4.02% | $72.98 (−8.13%) |
Jul 28, 2026 13w ago | Press Release | $79.44 $79.70 | ▲ +0.33% | ▼ −4.02% | $72.98 (−8.13%) |
May 26, 2026 22w ago | 8-K | $51.84 $78.47 | ▲ +51.37% | ▲ +49.49% | $72.98 (+40.78%) |
May 1, 2026 25w ago | 8-K | $57.62 $80.92 | ▲ +40.44% | ▲ +38.58% | $72.98 (+26.66%) |
Apr 28, 2026 26w ago | 144 | $52.99 $62.84 | ▼ −18.59% | ▼ −14.48% | $72.98 (−37.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers